Their findings showed that p16 expression was inconsistent and did not significantly correlate with clinicopathological features or patient outcomes, suggesting the limited value of this marker in predicting aggressive behavior in GIST. This evidence concerns the gene CDKN2A and gastrointestinal stromal tumor.